10-Q: Guardant Health Q3 Revenue Soars 39% on Shield Success, Narrows Losses

Guardant Health reported a 39% surge in third-quarter revenue, driven by strong adoption of its Shield colorectal cancer screening test and oncology portfolio, while significantly narrowing its net loss.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 39% to $265.2 million, up from $191.5 million in the prior year period.
• Net loss for the three months ended September 30, 2025, improved to $92.7 million, compared to a net loss of $107.8 million for the same period in 2024.
• Screening revenue, primarily from the Shield test, saw a substantial increase to $24.1 million for the quarter, delivering approximately 24,000 tests.
• Oncology revenue grew by 31% to $184.4 million, driven by an increase in test volume to approximately 74,000 tests.
• Biopharma and data revenue increased by 18% to $54.7 million, primarily due to the achievement of certain companion diagnostic development and regulatory approval service agreement milestones.
• For the nine months ended September 30, 2025, total revenue increased by 30% to $700.8 million, and net loss improved to $287.8 million from $325.4 million in the prior year period.
• Cash, cash equivalents, and restricted cash stood at $689.5 million as of September 30, 2025, an increase from $629.8 million at the beginning of the year.
• Operating cash flow improved, with net cash used in operating activities decreasing to $158.4 million for the nine months ended September 30, 2025, from $175.3 million in the prior year period.
• A gain on extinguishment of convertible notes of $13.7 million was recognized for the nine months ended September 30, 2025, related to a note exchange transaction.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth across its key segments, particularly in screening, and significantly narrowed its net loss. Key product milestones like FDA approval and Medicare coverage for Shield, coupled with a major legal victory, provide strong positive momentum. While still operating at a loss and facing ongoing legal challenges, the operational improvements and market penetration indicate a very positive trajectory.

Positives

• Total revenue increased by 39% for the three months ended September 30, 2025, and 30% for the nine months ended September 30, 2025, demonstrating strong growth across segments.
• Net loss significantly narrowed to $92.7 million for the quarter and $287.8 million for the nine months, indicating improved operational efficiency or revenue leverage.
• Screening revenue from the Shield blood test experienced substantial growth, with 24,000 tests delivered in the quarter, following FDA approval and Medicare coverage.
• The Shield blood test was included in the National Comprehensive Cancer Network's updated colorectal cancer screening guidelines in June 2025, enhancing market adoption.
• Received FDA Breakthrough Device designation for the Shield multi-cancer detection (MCD) test in June 2025, potentially accelerating its development and review.
• Expanded Shield blood test to include an MCD results report in October 2025, broadening its utility.
• Achieved a significant legal victory against Natera, Inc. in a false advertising dispute, with a jury awarding $292.5 million (affirmed at $287.0 million) and injunctive relief.
• Net cash used in operating activities decreased by $16.9 million for the nine months ended September 30, 2025, reflecting improved cash management from operations.
• Investing activities generated $277.9 million in cash for the nine months, a substantial improvement from a $271.8 million use in the prior year, primarily due to maturities of marketable debt securities.
• Successfully completed a Note Exchange Transaction in February 2025, which resulted in a $13.7 million gain on extinguishment of convertible notes.

Negatives

• Continued to incur net losses, with a net loss of $92.7 million for the quarter and $287.8 million for the nine months ended September 30, 2025.
• Total stockholders deficit increased significantly to $354.5 million as of September 30, 2025, from $139.6 million as of December 31, 2024.
• Interest income decreased by 44% for the quarter and 43% for the nine months, primarily due to reduced investment balances and lower market rates.
• Increased operating expenses across all categories (Cost of revenue, R&D, Sales & Marketing, G&A) in absolute dollars, reflecting continued investment but also contributing to losses.
• Incurred $60.9 million in net cash used in financing activities for the nine months, primarily due to a $45.0 million treasury stock repurchase and $12.3 million in debt issuance costs.

Risks

• Ongoing patent infringement lawsuits with TwinStrand Biosciences and the University of Washington, Tempus AI, Inc., and Cold Spring Harbor Laboratory, which could result in substantial payments, injunctions, or changes to business operations.
• Uncertainty and unpredictability of the reimbursement landscape for tests from third-party payers, which could lead to revenue fluctuations or reversals.
• Exposure to credit risk from accounts receivable, although the majority of customers have high credit ratings.
• Potential adverse impact of international geopolitical conditions, such as the bilateral relationship between the United States and China, on international partnerships and financial results.
• Two pending wage and hour class action lawsuits in California Superior Courts alleging violations of the California Labor Code, with unspecified monetary damages and penalties sought.
• The company expects to incur additional operating losses in the near future as it continues to invest in clinical studies and product development.

Future Outlook

The company expects to expand into lung cancer screening and multi-cancer detection with its Shield platform, with ongoing clinical studies like the SHIELD LUNG study and participation in the NCI-funded Vanguard study. Significant expenditures in research and development are anticipated to fuel further innovation. International expansion remains a long-term growth strategy, with increased sales and marketing efforts expected. The company believes its current cash, cash equivalents, restricted cash, and anticipated cash flows from operations will be sufficient to meet anticipated cash requirements for more than 12 months.

Management Comments

• We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.
• We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, and real-world data.
• Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
• We expect our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical studies.
• We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our tests.
• We expect that our general and administrative expenses will continue to increase as we incur additional costs to support the growth of our business.

Industry Context

The precision oncology and liquid biopsy market continues to be a high-growth area, driven by advancements in genomic profiling and the increasing demand for less invasive diagnostic tools. Guardant Health's strong revenue growth, particularly in its screening segment with the Shield test, positions it well within this expanding market. The FDA approval and Medicare coverage for Shield are critical milestones, setting a new standard for blood-based colorectal cancer screening and potentially accelerating broader adoption. The company's extensive R&D investments and strategic biopharma partnerships align with the industry trend towards integrated diagnostic and therapeutic development. The competitive landscape, as highlighted by the legal disputes with Natera and Tempus, underscores the intense competition and intellectual property battles inherent in this innovative sector.

Comparison to Industry Standards

• The Shield blood test's performance in the ECLIPSE study, demonstrating 83% sensitivity in detecting colorectal cancer and 90% specificity, exceeds the performance criteria set forth by the Centers for Medicare and Medicaid Services (CMS) for reimbursement.
• The company's legal victory against Natera, Inc. regarding false advertising claims related to Guardant Reveal versus Natera's Signatera assay, highlights competitive dynamics in the minimal residual disease (MRD) testing market.
• The company's Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the U.S. Food and Drug Administration (FDA) to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC) and breast cancer, setting an early benchmark in the field.

Management Changes

Legal Proceedings

• TwinStrand Biosciences, Inc. and the University of Washington filed a patent infringement suit in August 2021. A jury found willful infringement in November 2023, awarding $83.4 million in damages. The company is vigorously contesting the verdict, with post-trial motions filed in March 2024 and an appeal hearing on patent validity in October 2025.
• The company filed a patent infringement suit against Tempus AI, Inc. in June 2024, alleging infringement of five patents. Tempus moved to dismiss some patents as invalid, and a trial is set for October 2028.
• Tempus AI, Inc. filed a patent infringement lawsuit against the company in March 2025, alleging infringement of four patents related to bioinformatic analysis technology.
• Cold Spring Harbor Laboratory (CSHL) filed a patent infringement lawsuit against the company in March 2025, alleging infringement of U.S. Patent No. 10,947,589 related to gene sequencing and analysis technology. A Markman hearing is scheduled for April 2, 2026, and trial for April 19, 2027.
• The company filed a lawsuit against Natera, Inc. in May 2021 for false advertising. In November 2024, a jury found in favor of the company, awarding $292.5 million (later affirmed at $287.0 million) including punitive damages. Injunctive relief was granted in July 2025, preventing Natera from continuing false advertising.
• The company filed a declaratory judgment action against Tempus AI, Inc. in January 2025, seeking to show that Tempus's false advertising allegations are without merit. Tempus filed counterclaims, and a trial is set for September 2027.
• The company is a defendant in two wage and hour class action lawsuits in California Superior Courts, alleging violations of the California Labor Code, including claims for unpaid wages, overtime, and meal/rest period violations. The outcome remains uncertain at this early stage.

Stakeholder Impact

• Shareholders: Potential for increased share price due to strong revenue growth, improved net loss, and significant product milestones (Shield FDA approval, Medicare coverage). However, ongoing legal disputes and continued unprofitability pose risks.
• Customers (Patients & Physicians): Expanded access to advanced cancer diagnostics and screening tests, particularly with the commercial availability and broad coverage of the Shield test, potentially leading to earlier detection and improved outcomes.
• Biopharmaceutical Partners: Continued collaboration opportunities through GuardantINFORM and GuardantINFINITY platforms, accelerating drug development and research.
• Employees: Stock-based compensation plans are in place to incentivize and retain talent. However, pending wage and hour class action lawsuits could impact employee relations and financial resources.
• Creditors: The company's improved cash position and reduced net cash used in operating activities may enhance its creditworthiness, while the convertible senior notes represent significant long-term debt obligations.

Next Steps

• Continue patient enrollment for the Shield post FDA-approval SOLAR study, aiming for conclusion by 2031.
• Continue the SHIELD LUNG study to clinically validate the next-generation Shield blood test for lung cancer screening.
• Enroll up to 24,000 people in the NCI-funded Vanguard study for the Shield multi-cancer detection (MCD) test.
• Attend the Markman hearing scheduled for April 2, 2026, in the Cold Spring Harbor Laboratory patent infringement lawsuit.
• Prepare for trial in the Tempus AI, Inc. false advertising dispute, set for September 2027.
• Prepare for trial in the company's patent infringement suit against Tempus AI, Inc., set for October 2028.
• Continue to vigorously contest the jury verdict and judgment in the TwinStrand Biosciences patent infringement suit through post-trial motions and potential appeal.

Key Dates

Recommendation

Guardant Health's latest 10-Q filing presents a compelling case for a 'Buy' recommendation, particularly for growth-oriented investors. The company demonstrated robust revenue growth of 39% for the quarter and 30% year-to-date, driven by strong adoption of its oncology portfolio and the highly successful commercialization of its Shield colorectal cancer screening test. The FDA approval, Medicare coverage, and NCCN inclusion for Shield are transformative milestones, positioning the company as a leader in a rapidly expanding market. Furthermore, the significant narrowing of net losses and improved operating cash flow indicate a positive trajectory towards profitability. The substantial legal victory against Natera, Inc., with a large damages award and injunctive relief, removes a significant overhang and validates the company's competitive standing. While ongoing legal challenges and continued unprofitability warrant monitoring, the strong product pipeline, market penetration, and operational improvements suggest significant long-term upside potential.

Keywords

Precision Oncology, Liquid Biopsy, Cancer Screening, Colorectal Cancer, Shield Test, Guardant360, Guardant Reveal, FDA Approval, Medicare Coverage, Biopharma Partnerships, Genomic Profiling, Diagnostics, SEC Filing, 10-Q